37620-39-6

Upstream product

• 92-52-4 biphenyl 
• 92-91-1 biphenyl-4-acetaldehyde 
• 104-87-0 4-methyl-benzaldehyde 

Downstream Products

• 65205-52-9 3-biphenyl-4-yl-5-p-tolyl-isoxazole 
• 76287-95-1 3-Biphenyl-4-yl-5-p-tolyl-4,5-dihydro-isoxazole 
• 1027402-10-3 4-biphenyl-4-yl-2-oxo-6-p-tolyl-cyclohex-3-enecarboxylic acid ethyl ester 
• 1017240-36-6 C₂₂H₂₀N₂ 
• 861406-46-4 C₂₆H₂₅N₃O 
• 1026691-61-1 3-biphenyl-4-yl-5-p-tolyl-cyclohex-2-enone 

Relevant academic research and scientific papers

Pyrimidine-2-amine derivative, a method for producing the same, and an anticancer drug containing the same

The present invention relates to a pyrimidine-2-amine derivative, a method for manufacturing the same, and an anticancer drug containing the same. The pyrimidine-2-amine derivative represented by chemical formula 1 according to the present invention has a

Synthesis and characterization of 2-phenylpyrazoline derivatives and evaluation of their activities against antimicrobial and breast cancer cell line in vitro and in silico studies

The new series of 2-phenylpyrazoline derivatives (2a-j) were synthesized and evaluated for their antimicrobial, in silico and in vitro anticancer activity was performed by MTT assay using MDA-MB-231 (human breast adenocarcinoma) cell line. The 2-phenylpyr

Design, synthesis, and biological evaluation of polyphenols with 4,6-diphenylpyrimidin-2-amine derivatives for inhibition of Aurora kinase A

Background: Several 4,6-diarylpyrimidin-2-amine derivatives show anticancer properties. However, their mode of action is not fully characterized. To develop potent anticancer chemotherapeutic agents, we designed and synthesized 25 4,6-diphenylpyrimidin-2-amine derivatives containing a guanidine moiety. Methods: Clonogenic long-term survival assays were performed to screen anticancer compounds. To derive the structural conditions showing good cytotoxicities against cancer cells, quantitative structure-activity relationships (QSAR) were calculated. Biological activities were determined by flow cytometry for cell cycle analysis and by immunoblot analysis for the detection of Aurora kinase A (AURKA) activity. Because 2-(2-Amino-6-(2,4-dimethoxyphenyl)pyrimidin-4-yl) phenol (derivative 12) selectively inhibited AURKA activity from the kinome assay, in silico docking experiments were performed to elucidate the molecular binding mode between derivative 12 and AURKA. Results: The pharmacophores were derived based on the QSAR calculations. Derivative 12 inhibited AURKA activity and reduced phosphorylation of AURKA at Thr283 in HCT116 human colon cancer cells. Derivative 12 caused the accumulation of the G2/M phase of the cell cycle and triggered the cleavages of caspase-3, caspase ?7, and poly(ADP-ribose) polymerase. The binding energies of 30 apo-AURKA – derivative 12 complexes obtained from in silico docking ranged from ?16.72 to ?11.63 kcal/mol. Conclusions: Derivative 12 is an AURKA inhibitor, which reduces clonogenicity, arrests the cell cycle at the G2/M phase, and induces caspase-mediated apoptotic cell death in HCT116 human colon cancer cells. In silico docking demonstrated that derivative 12 binds to AURKA well. The structure-activity relationship calculations showed hydrophobic substituents and 1-naphthalenyl group at the R2 position increased the activity. The existence of an H-bond acceptor at C-2 of the R1 position increased the activity, too.

Synthesis and characterization of 2-pyrazoline derivatives and their in silico and in vitro studies on antimicrobial and anticancer activities

The new series of 1-(4,5-dihydro-5-phenyl-3-diphenylpyrazol-1-yl)butan-1-one derivatives were synthesized by cyclization method using biphenyl chalcone with n-butyric acid and hydrazine hydrate. The synthesized 1-(4,5-dihydro-5-phenyl-3-diphenylpyrazol-1-

Pyrimidine-2-amine derivative, a method for producing the same, and an anticancer drug containing the same

The present invention relates to a pyrimidine-2-amine derivative, a method for manufacturing the same, and an anticancer agent comprising the same. The pyrimidine-2-amine derivative represented by chemical formula 1 according to the present invention has

An efficient synthesis and in vitro antimicrobial screening of 2-cyanoimino-4-aryl-6-(1,1′-biphenyl-4-yl)-3, 4-dihydro-1H-pyrimidines

An efficient synthesis of 2-Cyanoimino-4-aryl-6-(1,1′-biphenyl-4-yl)-3,4-dihydro-1H-pyrimidines from stryl-4-biphenylketones and cyanoguanidine in presence of sodium hydroxide has been described. Cyanoguanidine serves as N-C=N source for the construction of desired cyanoiminopyrimidines. The structural assignments of the titled products were done accordingly to their spectra like Mass, FT-IR, Proton and Carbon-13NMR spectroscopy. The more stable tautomeric form was ascertained using computational frequency analysis. The tested microorganism profile of compounds exhibits significant antimicrobial activity.

Synthesis and antibacterial activity of some 5-(4-biphenylyl)-7-aryl[3,4-d] [1,2,3]-benzothiadiazoles

A series of 5-(4-biphenylyl)-7-aryl[3,4-d] [1,2,3]-benzothiadiazoles were synthesized, characterized by IR, NMR and elemental analysis and evaluated for in vitro antibacterial activity against some Gram-positive and Gram-negative bacteria. The antibacterial data revealed that compounds 7a-j had better activity against tested Gram-positive organisms than the reference ciprofloxacin and norfloxacin. However, the compounds were nearly inactive against Gram-negative bacteria. Compound 7c and 7d were the most active compounds against Gram-positive bacteria.

Substituent effects on 1H and 13C NMR chemical shifts in styryl fluorenyl and styryl biphenyl ketones

Several substituted styryl 2-fluorenyl ketones and styryl 4-biphenyl ketones have been prepared and their 1H and 13C NMR spectra recorded. While the chemical shifts of β-protons and β-carbons in styryl 2-fluorenyl ketones exhibit goo